Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Mesothelioma
- Main trialPhase 1
- “The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.”In the company’s words, NCT04857372 on ClinicalTrials.gov
Other drugs for Mesothelioma
- VT3989Vivace Therapeutics, Inc · Phase 3
- VolrustomigAstraZeneca · Phase 3
- EB-MF-CAR-NK-01Beijing Biotech · Phase 1/2
- PembrolizumabMerck & Co. · Phase 2
- VopimetostatTango Therapeutics, Inc. · Phase 1/2
- ISM6331InSilico Medicine Hong Kong Limited · Phase 1/2
Coming up1
- 7 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 7 Jan 2027 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026